Vanguard Group Inc Viridian Therapeutics, Inc.\De Call Options Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRDN
# of Institutions
188Shares Held
83.9MCall Options Held
50.5KPut Options Held
94.1K-
Deep Track Capital, LP Greenwich, CT5.38MShares$155 Million3.65% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$137 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$127 Million8.05% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$112 Million12.69% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.46MShares$99.4 Million16.2% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $1.15B
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...